Release Details
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
The ASGCT abstracts are now available at https://www.asgct.org/.
Details for the oral presentations are as follows:
Title: Development of AAV-based RNAi Therapeutics for Huntington’s Disease
Session: Scientific Symposium
Date/time:
Title: Engineering Viral Protein Ratios to Impact AAV Potency
Session: AAV Vectors - Clinical Studies II
Date/time:
Title: Lac Repressor Inducible Control of AAV Capsid Protein Ratios and Decoupling VP1, VP2 from VP3 in the Sf9 insect cell/Baculovirus Expression Vector (BEV) Platform
Session: Vector and Cell Engineering, Production, or Manufacturing IV
Date/time:
Details for the poster presentations are as follows:
Title: Phenotypic Benefit of
Session: AAV Vectors - Preclinical and Proof-of-Concept Studies
Date/time:
Title: Intraparenchymal Spinal Cord Delivery of AAV VY-SOD102 Reduces Disease Burden in the G93A Mouse Model of ALS-SOD1
Session: AAV Vectors - Preclinical and Proof-of-Concept Studies
Date/time:
Title: Robust Scale-Up and Production of Multiple Gene Therapy Vectors for Pre-Clinical Applications at 250 L Scale with the Sf9: Baculovirus Expression System
Session: Vector and Cell Engineering, Production, or Manufacturing
Date/time:
Title: Successful Technology Transfer and Clinical Manufacturing for AAV Gene Therapy Vectors: Lessons from Multiple Campaigns
Session: AAV Vectors - Clinical Studies
Date/time:
Title: A Novel AAV Capsid with a Potential of Crossing NHP Blood
Session: AAV Vectors - Virology and Vectorology
Date/time:
Title: Transduction of Various Fragment Forms of Vectorized Anti-Tau Antibodies Using IV Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mice
Session: Neurologic Diseases
Date/time:
Title: Critical Sf9 Metabolites for Baculovirus Infection and AAV Production
Session: Vector and Cell Engineering, Production or Manufacturing
Date/time:
Title: Analytical Testing Strategy for AAV Vectors Produced by the Baculovirus/Sf9 System
Session: Pharmacology/Toxicology Studies or
Date/time:
Title: Phase-Appropriate Viral Clearance Strategy for Sf9/Baculovirus Based Manufacturing of Gene Therapy Products
Session: Vector and Cell Engineering, Production or Manufacturing
Date/time:
Title: Strategic Formulation Development Approach for Early Stage rAAV Mediated Gene Therapy Programs for CNS Indications
Session: Vector and Cell Engineering, Production, or Manufacturing
Date/time:
Title: Capillary Electrophoresis as a Tool to Assess Multiple Attributes of AAV Based Therapeutics
Session: AAV Vectors - Virology and Vectorology
Date/time:
About
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding our expectation to make multiple data presentations at the 2020 Annual Meeting of the
Investors:
VP, Investor Relations
917-754-0207
pcox@vygr.com
Media:
W2Opure
949-903-4750
sseapy@purecommunications.com
Source: Voyager Therapeutics, Inc.